Longwood closes fund at $87 million
This article was originally published in Scrip
Longwood Founders Management, a Boston, Massachusetts-based healthcare venture capital firm, has closed of its first fund, Longwood Founders Fund, at $86.9 million, according to its SEC filing. Founded by biotech entrepreneurs, Richard Aldrich, Dr Michelle Dipp and Dr Christoph Westphal, Longwood will concentrate on establishing and building biotech companies with breakthrough science focusing on therapeutics.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.